Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Along with the new oral version of the GLP-1 agonist that has made a strong commercial start since its launch in the US earlier this year, the high-dose injectable version is one of the assets Novo Nordisk is hoping will help staunch the loss in market share in obesity caused by the rapid growth of Wegovy's main rival, Eli Lilly's Zepbound/Mounjaro (tirzepatide), which outperformed the original 2.4 mg Wegovy formulation in head-to-head trials
It is a question increasingly asked as interest in novel weight-management and hormone-optimising compounds grows, but the answer is far from straightforward
Note: all pricing tiers include access to the Semaglutide plan
Formulated Men's and Women's Daily Care Probiotics for Digestive Gut Health and Immune Support, 25 Billion CFU, 30 Count 2514.6 out of 5 Stars
US$ 25.86
US$ 25.08
US$ 28.82
US$ 26.86
